Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board.

“Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers,” said Matt Angel, Ph.D., President and CEO of Tempest. “The addition of Drake and John to the Board could further enable us to realize our vision of providing meaningful treatment options to cancer patients that have either failed or relapsed from prior therapies, while supporting Tempest’s focus on driving growth and disciplined capital allocation. I look forward to Drake’s and John’s insights as we continue to position the Company for long-term success.”

About Drake Richey

Drake Richey serves as President of Bush & Company, a financial advisory firm that advises high-net-worth families and business owners on investment strategy, risk management, and multi-generational planning. Mr. Richey previously served as President of Life Check, an independent insurance policy review firm serving investment fiduciaries, professional trustees, and trusted advisors, as Vice President, Portfolio Manager at Wells Fargo, as and Director at Fitch Ratings. Mr. Richey is a founding member of the Boston Chapter of the Exit Planning Institute and has served on the boards of DEAF Inc., International Fellowship House, and Park Street Church. Mr. Richey earned a Bachelor of Science degree from Trinity College.

About John Yee, MD, MPH

John Yee MD, MPH, is Senior Vice President, Medical Affairs at Apnimed, Inc. Dr. Yee previously served as Chief Medical Officer at Sobi North America, Senior Vice President, Medical Affairs at Flexion Therapeutics, Inc., Senior Vice President and Global Head of Medical Affairs at Vertex Pharmaceuticals, Inc., Vice President, Medical Affairs, Safety and Operations at Intarcia Therapeutics, Inc., and Vice President, US Head Medical Officer and Vice President and Head of Medical Affairs for the US Diabetes franchise at AstraZeneca Pharmaceuticals, and in various medical leadership roles at Genzyme Corporation, including Vice President, US Medical Affairs, Vice President, Global Medical Affairs, and Vice President, Global Head, Evidence-Based Medicine and Health Outcomes Research. Dr. Yee earned his MD at Harvard Medical School and MPH in Health Care Management from the Harvard T.H. Chan School of Public Health. Dr. Yee previously held leadership roles at Boston Children’s Hospital and served as a faculty member at Harvard Medical School. Dr. Yee previously served as an independent director on the board of Comera Life Sciences.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at https://www.tempesttx.com.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest Therapeutics. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: the anticipated contributions of the newly appointed directors; the strategic growth, capital allocation and long-term success of Tempest Therapeutics; and Tempest Therapeutics’ ability to achieve its operational plans. All forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest Therapeutics’ need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest Therapeutics from time to time with the SEC. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.

Investor Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]



Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

PR Newswire

NEW YORK, June 4, 2026 /PRNewswire/ — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab’s potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.

If you currently own RARE and purchased prior to August 03, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-ultragenyx-pharmaceutical-inc-to-contact-law-firm-302791924.html

SOURCE Kuehn Law, PLLC

Knight-Swift Transportation Holdings Inc. Announces Retirement of Kevin Knight

Knight-Swift Transportation Holdings Inc. Announces Retirement of Kevin Knight

PHOENIX–(BUSINESS WIRE)–
Knight-Swift Transportation Holdings Inc. (NYSE: KNX) (the “Company” or “Knight-Swift”) announced today that Kevin P. Knight, one of the founders of Knight Transportation, former Chief Executive Officer from 1994 to 2014 and Executive Chairman of the board of directors, is retiring from the Company. This milestone follows a long and distinguished career including consequential leadership roles at each of Swift Transportation and Knight Transportation, and later at Knight-Swift Transportation following a highly successful 2017 merger of the two companies. The Board of Directors has appointed Lead Independent Director David Vander Ploeg as Chairman, effective June 3rd. Mr. Knight has agreed to continue serving the Company as a consultant for a period of two years following his retirement as Executive Chairman.

Mr. Knight commented, “I am humbled when I reflect on what we have built together and where our company stands today. There is so much to be proud of, and even more to be grateful for when I consider all of the family, coworkers, customers, suppliers, partners, and other stakeholders who have been part of our brands’ shared success, especially our driving associates, whose professionalism and dedication have helped make that success possible. As I have been approaching this transition in recent years, I knew this bridge would have to be crossed at some point. For me, our merger with Knight and Swift was our greatest collective achievement. The reunification of the Swift and Knight families, combined with timing, diligence, operational improvements, and significant financial returns, enabled us to achieve everything that followed. I am deeply grateful to everyone whom I have had the opportunity to work with.”

Adam Miller, Chief Executive Officer of Knight-Swift, said: “It cannot be overstated what Kevin has meant to our company, so many of our leaders, including myself, and so many more within our industry. Our leaders do not take lightly the trust placed in us to continue building on such a distinguished foundation. I am just one of many who are deeply grateful for all Kevin has done for us, personally and professionally over the years. The culture Kevin helped instill which prioritizes safety, operational excellence, and financial discipline is deeply rooted and will continue to mark our efforts to take Knight-Swift to new heights.”

About Knight-Swift

Knight-Swift is one of North America’s largest and most diversified freight transportation companies providing multiple full truckload, LTL, intermodal, and logistics services. Knight-Swift uses a nationwide network of business units and terminals in the United States and Mexico to serve customers throughout North America. In addition to operating one of the country’s largest tractor fleets, Knight-Swift also contracts with third-party equipment providers to provide a broad range of transportation services to our customers while creating quality driving jobs for our driving associates and successful business opportunities for independent contractors.

Adam Miller, CEO, Andrew Hess, CFO, or Brad Stewart, Treasurer and SVP – (602) 606-6349

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Trucking Transport Logistics/Supply Chain Management

MEDIA:

Logo
Logo

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.

Details of the oral presentation are as follows:

Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation
Session: Immune Modulatory Strategies for Next-Generation Cell Therapies
Date: Sunday, June 7, 2026
Time: 2:30 p.m. – 3:00 p.m. CT
Room: 343 (Level 3)

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedInTwitter

Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]

Media Contact:
Jenna Urban
CG Life
(212) 253 8881
[email protected]

Source: Eledon Pharmaceuticals



Prologis to Announce Second Quarter 2026 Results July 16, 2026

PR Newswire

SAN FRANCISCO, June 4, 2026 /PRNewswire/ — Prologis, Inc. (NYSE: PLD) will host a webcast and conference call with senior management to discuss its second quarter results, current market conditions and future outlook on Thursday, July 16, 2026, at 9:00 a.m. PT/12:00 p.m. ET.

To access a live broadcast of the call, please dial +1 (877) 897-2615 (toll-free from the United States and Canada) or +1 (201) 689-8514 (from all other countries). A live webcast can be accessed from the Investor Relations section of www.prologis.com.

A telephonic replay will be available July 16 – July 30 at +1 (877) 660-6853 (from the United States and Canada) or +1 (201) 612-7415 (from all other countries) using access code 13757425. The webcast replay will be posted in the Investor Relations section of www.prologis.com under “Events & Presentations.”

About Prologis

The world runs on logistics. At Prologis, we don’t just lead the industry, we define it. We create the intelligent infrastructure that powers global commerce, seamlessly connecting the digital and physical worlds. From agile supply chains to clean energy solutions, our ecosystems help your business move faster, operate smarter and grow sustainably. With unmatched scale, innovation and expertise, Prologis is a category of one–not just shaping the future of logistics but building what comes next. Learn more at Prologis.com.

Forward-Looking Statements
The statements in this document that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which we operate as well as management’s beliefs and assumptions. Such statements involve uncertainties that could significantly impact our financial results. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” and “estimates” including variations of such words and similar expressions are intended to identify such forward-looking statements, which generally are not historical in nature. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future—including statements relating to rent and occupancy growth, acquisition and development activity, including data center developments and power procurement related thereto, contribution and disposition activity, general conditions in the geographic areas where we operate, expectations regarding new lines of business, our debt, capital structure and financial position, our ability to earn revenues from co-investment ventures, form new co-investment ventures and the availability of capital in existing or new co-investment ventures—are forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, we can give no assurance that our expectations will be attained and, therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Some of the factors that may affect outcomes and results include, but are not limited to: (i) international, national, regional and local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including the integration of the operations of significant real estate portfolios; (v) maintenance of Real Estate Investment Trust status, tax structuring and changes in income tax laws and rates; (vi) availability of financing and capital, the levels of debt that we maintain and our credit ratings; (vii) risks related to our investments in our co-investment ventures, including our ability to establish new co-investment ventures; (viii) risks of doing business internationally, including currency risks; (ix) environmental uncertainties, including risks of natural disasters; and (x) those additional factors discussed in reports filed with the Securities and Exchange Commission by us under the heading “Risk Factors.” We undertake no duty to update any forward-looking statements appearing in this document except as may be required by law.

Prologis. (PRNewsFoto/Prologis, Inc.) (PRNewsFoto/Prologis, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/prologis-to-announce-second-quarter-2026-results-july-16-2026-302791931.html

SOURCE Prologis, Inc.

Telesat announces results of 2026 Annual General Meeting of shareholders

OTTAWA, Ontario, June 04, 2026 (GLOBE NEWSWIRE) — Telesat Corporation (Nasdaq and TSX: TSAT) (“Telesat” or the “Company”), one of the world’s largest and most innovative satellite operators, today announced the voting results from its annual general meeting of shareholders held on June 3rd virtually via live audio webcast.

Shareholders of Telesat voted in favour of all items of business, including the appointment of Deloitte LLP Chartered Professional Accountants as auditors of the Company and the election of each of the director nominees as follows:

 
Director Nominee


Votes For

Votes Withheld
(a) Michael Boychuk 47,065,688 378,951
(b) Jane Craighead 46,234,918 1,209,721
(c) Richard Fadden 47,326,278 112,361
(d) Daniel S. Goldberg 47,325,708 118,931
(e) Henry (Hank) Intven 46,632,946 811,693
(f) David Morin 47,121,302 323,337
(g) Dr. Mark H. Rachesky 46,122,864 1,321,775
(h) Guthrie Stewart 46,230,246 1,214,393
(i) Michael B. Targoff 47,326,802 117,837
(j) Janet Yeung 47,325,092 119,547
       

Final voting results on all matters voted on at the meeting will be filed on SEDAR+ at https://www.sedarplus.ca/ and on EDGAR at https://www.sec.gov/.

About Telesat

Backed by a legacy of engineering excellence, reliability and industry-leading customer service, Telesat (Nasdaq and TSX: TSAT) is one of the largest and most innovative global satellite operators. Telesat works collaboratively with its customers to deliver critical connectivity solutions that tackle the world’s most complex communications challenges, providing powerful advantages that improve their operations and drive profitable growth.

Continuously innovating to meet the connectivity demands of the future, Telesat Lightspeed, the company’s Low Earth Orbit (LEO) satellite network, has been optimized to meet the rigorous requirements of telecom, government, maritime and aeronautical customers. Telesat Lightspeed will redefine global satellite connectivity with ubiquitous, affordable, high-capacity, secure and resilient links with fibre-like speeds. For updates on Telesat, follow us on LinkedIn, X, or visit www.telesat.com.

Investor Relations contact:

James Ratcliffe
+1 613 748 8424
[email protected]



Satellogic to Participate in June Investor Conferences

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) — Satellogic, Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence, today announced that it will participate in-person at the 16th Annual ROTH London Conference taking place at the Hotel London in London on June 16 – 18, and virtually at the Northland Growth Conference taking place on June 23.

Emiliano Kargieman, Chief Executive Officer & Founder, and Ryan Driver, Senior Vice President of Finance & Corporate Development, will attend the 16th Annual ROTH London Conference and will be available for in-person one-on-one meetings with investors. Mr. Driver will also attend the Northland Growth Conference and will be available for virtual one-on-one meetings with investors.

16th Annual ROTH London Conference

Date: June 16 – 18, 2026
Location: Hotel London at Park Lane, London, UK
Format: In-person 1×1 Meetings
Attendees: Chief Executive Officer & Founder Emiliano Kargieman and SVP of Finance & Corporate Development Ryan Driver
Website: click here

Northland Growth Conference

Date: June 23, 2026
Location: Virtual
Format: Virtual 1×1 Meetings
Attendee: SVP of Finance & Corporate Development Ryan Driver
Website: click here

For more information on the 16th Annual ROTH London Conference, Northland Growth Conference, or to schedule a meeting with Satellogic management, please contact your conference representative or Satellogic’s Investor Relations at [email protected].

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) is building the infrastructure for Persistent Global Intelligence: continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-capable architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves defense and intelligence agencies, allied governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, our plans, strategies, prospects, both business and financial. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to the risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Satellogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Satellogic can give no assurance that it will achieve its expectations.

Contacts

Investor Relations:
[email protected]

Media Relations:
[email protected]



Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets

  • Charger Hub takes center stage at Booth 1416, with the full Xos electric portfolio available for review
  • Xos team will be available at Booth 1416 throughout GFX 2026 to discuss fleet electrification timelines, total cost of ownership, and infrastructure requirements with public fleet managers

LOS ANGELES, June 04, 2026 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a technology company and fleet services provider specializing in battery-electric fleet solutions and mobile energy storage infrastructure, today announced its appearance at the Government Fleet Expo and Conference (GFX) 2026. The event takes place June 9 to 12 at the Long Beach Convention Center in Long Beach, California, where Xos will exhibit at Booth 1416. Xos has served commercial and municipal fleet operators since 2018 and counts among its customers Waymo, Caltrans, FedEx ISPs, UPS, Loomis, and Cintas.

Public fleet managers operate under constraints that commercial fleets rarely face: fixed procurement cycles, tight capital budgets, and accountability to taxpayers. At Booth 1416, Xos has the answers.

Xos at GFX 2026:

  • Xos will present its full product portfolio at GFX, including the Charger Hub mobile and stationary energy storage system, which allows public fleets to add charging capacity without costly grid upgrades or utility interconnection delays.
  • The Company’s electric powertrains are integrated into electric school buses operating across school districts in North America, providing a field-validated proof point of Xos’s ability to supply drivetrain technology at scale for vehicle manufacturers and OEM partners.
  • Xos electric step vans and Class 8 trucks serve customers with demanding duty cycles in last-mile delivery and regional haul operations, accumulating millions of miles in commercial service with fleet operators including UPS, FedEx, and Cintas.
  • Government fleet managers face a distinct set of procurement constraints, budget cycles, and uptime requirements. Xos vehicles and energy systems are purpose-built for reliability and total cost of ownership, two of the most critical metrics for public sector fleet decisions.
  • GFX 2026 marks Xos’s first appearance at the conference, a deliberate step to engage directly with municipal, state, and federal fleet decision-makers as public agencies advance their electrification commitments under local and state zero-emission mandates.

“Government fleets are some of the most demanding operators in the country, and they deserve the same access to proven electric technology that commercial fleets have had for years. At Xos, we have built products that perform in the real world, not just on spec sheets. GFX is where we connect with the people making those fleet decisions, and we are ready to show them what electricity can actually do,” said Dakota Semler, Chief Executive Officer of Xos.

GFX 2026 arrives as public agencies across the country face mounting pressure to meet zero-emission targets with budgets and infrastructure that were never designed for electrification. With the Xos Hub™ removing the grid upgrade barrier, field-validated powertrain technology already in service in public sector vehicles, and a team that has worked with municipal and government operators since 2018, Xos steps onto the GFX floor for the first time with experience that speaks directly to the challenges public fleet managers face today.

Fleet managers and procurement officers interested in meeting with Xos at GFX 2026 can visit Booth 1416 during Expo Hall hours, June 9 to 12, at the Long Beach Convention Center. To schedule a meeting in advance, contact the team at [email protected] or visit www.xostrucks.com.

About Xos

Xos, Inc. (NASDAQ: XOS) is a leading energy storage and fleet electrification solutions provider. The Xos Hub is a proactive, movable power source delivering high-capacity output and high-speed charging in one. Xos vehicles, powertrains and fleet management software are purpose-built for medium- and heavy-duty commercial vehicles that travel on last-mile, back-to-base routes. The Company leverages its proprietary technologies to provide a diverse customer base with rapid-deployment energy storage and charging solutions and commercial fleets with battery-electric vehicles that are easier to maintain and more cost-efficient on a total cost of ownership (TCO) basis than their internal combustion engine counterparts. For more information, please visit www.xostrucks.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding projected financial and performance information; expectations and timing related to product deliveries and customer demand; sufficiency of existing cash reserves; customer acquisition and order metrics; ability to access additional capital and Xos’s long-term strategy and future growth. These forward-looking statements may be identified by the words “anticipate,” “believe,” “continue,” “likely,” “plan,” “possible,” “potential,” “predict,” “project,” “seem,” “seek,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might,” “could,” “should,” “will,” “would,” and similar expressions and any other statements that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) Xos’s liquidity and access to capital when needed, including its ability to service its indebtedness; (ii) cost increases and delays in production due to supply chain shortages in the components needed for the production of Xos’s vehicle chassis and battery system; (iii) the ability of products and/or components to perform as designed or expected; (iv) Xos’s ability to implement its business plan or meet or exceed its financial projections; (v) Xos’s ability to retain key personnel and hire additional personnel, particularly in light of current and potential labor shortages; (vi) the risk of downturns and a changing regulatory landscape in the highly competitive electric vehicle industry; and (vii) macroeconomic and political conditions. All forward-looking statements included in this press release are expressly qualified in their entirety by, and you should carefully consider, the foregoing factors and the other risks and uncertainties described under the heading “Risk Factors” included in Xos’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2025 and Xos’s other filings with the SEC, copies of which may be obtained by visiting Xos’s Investors Relations website at https://www.xostrucks.com/sec-filings or the SEC’s website at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Xos assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Xos does not give any assurance that it will achieve its expectations.

Media Contact:

[email protected]

Investor Contact:

Xos Investor Relations


[email protected]



TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology

European Union Market Expansion Advances with Official Authorization in Austria and Italy

FREDERICK, Md., June 04, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, has secured official regulatory approval for its Binary Ionization Technology (BIT) in additional European Union member states. This milestone marks a significant step forward in the Company’s European market expansion, with Austria and Italy joining the list of authorized countries. With these new additions, TOMI’s innovative disinfection product is now approved for use in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Great Britain, and Northern Ireland. Notably, the product has been officially authorized as a PT2 disinfectant in the Netherlands since March 2026.

The regulatory milestone was achieved under the European Union’s Biocidal Products Regulation (BPR), which standardizes the authorization of biocidal products throughout the EU. Because the BPR allows an approval in one member state to support a streamlined mutual recognition process in others, TOMI can significantly accelerate its market rollout without repeating full, independent authorization procedures in every country. Looking ahead, parallel mutual recognition is anticipated to bring the technology to France, Ireland, Poland, Portugal, Romania, and Spain.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit https://www.steramist.com or contact us at [email protected].

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the European market. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:  

John Nesbett/Zach Nevas

IMS Investor Relations  

[email protected]  



Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

MIAMI–(BUSINESS WIRE)–
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab.

The presentation will be available live through the company’s website: www.smmttx.com. An archived version of the presentation will be available on the website following the presentation.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company’s shares are listed on the Nasdaq Global Market (symbol “SMMT”). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Summit Forward-Looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company’s anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study that with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.

Summit Investor Relations & Media Contacts:

Nathan LiaBraaten

Senior Director, Investor Relations

Tracy Jones

Director, Media & Public Relations

[email protected]

[email protected]

KEYWORDS: California Florida United States North America

INDUSTRY KEYWORDS: Research Clinical Trials Biotechnology Health Pharmaceutical General Health Other Science Science Oncology

MEDIA:

Logo
Logo